Already have an account?


Login with an existing Projects In Knowledge account Log in with your MPT account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy
Education Initiative in Hematology

  • Leukemia — Case Study in Chronic Lymphocytic Leukemia: Management of a Patient With Ibrutinib-Resistant CLL – @Point of Care Chapter
  • This case illustrates the real-life clinical scenario of a patient with recurrent chronic lymphocytic leukemia with a chromosome 17p deletion who develops ibrutinib resistance. The available therapeutic options for patients with ibrutinib-resistant disease are discussed. Throughout this activity you will find ... more >>
    S. Kim, MD
    P. Venugopal, MD
  • Multiple Myeloma — High-Risk Relapsing MM: Retreatment With Immunomodulatory Therapy – Case Study
  • Determination of the best treatment for a high-risk multiple myeloma patient is based on a complex set of factors, including risk evaluation, patient comorbidities, patient desires, and the need to achieve a satisfactory response as quickly as possible. In this case, Dr. Lentzsch discusses the problems ... more >>
    S. Lentzsch, MD, PhD
  • Leukemia — Case Study in Chronic Lymphocytic Leukemia: Management of a Previously Untreated Patient With Symptomatic CD20-Positive CLL Requiring Treatment – @Point of Care Chapter
  • This activity in the Chronic Lymphocytic Leukemia @Point of Care program reviews the real-life case scenario of an elderly patient with symptomatic chronic lymphocytic leukemia and renal cell carcinoma. It highlights the available first-line therapeutic options for patients who are older and/or frail and have ... more >>
    R. Karmali, MD, MS
  • Multiple Myeloma — Relapsing/Refractory Multiple Myeloma in a High Risk Patient: Efficacy With Monoclonal Antibody Therapy as Part of Triple Therapy – Case Study
  • Choosing the appropriate therapy for transplant-deferred patients with relapsed multiple myeloma (MM) can be challenging; there are now emerging combination treatments available, each with their own efficacy and safety profiles. This case illustrates the real-life case scenario of a patient with relapsed MM ... more >>
    N. Raje, MD
  • Leukemia — Emerging Treatment Strategies in Chronic Lymphocytic Leukemia – @Point of Care Chapter
  • The new era of targeted therapies for chronic lymphocytic leukemia (CLL) is completely transforming the future treatment of CLL. Recently approved targeted therapies have produced phenomenal outcomes, and these outcomes have led the drive for additional targeted therapies to meet remaining unmet needs, such ... more >>
    N. Jain, MD
    S. O'Brien, MD, MA, BA
  • Leukemia — Assessment and Management of Chronic Lymphocytic Leukemia in the Elderly – @Point of Care Chapter
  • Elderly patients with chronic lymphocytic leukemia (CLL) have traditionally been considered a vulnerable and difficult-to-treat population. With advancing patient age the number of comorbid conditions will typically increase, while functional status may decline, presenting the need for careful assessment and ... more >>
    J. Katsetos, PA-C
    K. Rai, MD, BS
  • Leukemia — Management Principles in Chronic Lymphocytic Leukemia – @Point of Care Chapter
  • When should a patient with chronic lymphocytic leukemia (CLL) start therapy? When should a patient be monitored in a “watch-and-wait” approach? What are the criteria for complete and partial therapeutic responses and how do those criteria vary with new targeted therapies, such as ibrutinib and venetoclax? In ... more >>
    N. Jain, MD
    S. O'Brien, MD, MA, BA
  • Leukemia — Current Treatment Strategies in Chronic Lymphocytic Leukemia – @Point of Care Chapter
  • Five targeted therapies for chronic lymphocytic leukemia (CLL) have been approved for new indications since 2013, including obinutuzumab and ofatumumab, which are anti-CD20 monoclonal antibodies; ibrutinib, a Bruton’s tyrosine kinase inhibitor; idelalisib, a phosphoinositide 3-kinase delta inhibitor; and ... more >>
    N. Jain, MD
    S. O'Brien, MD, MA, BA
  • Multiple Myeloma — Hematology Mastery in Multiple Myeloma Video Roundtable – Video Presentation
  • Many scientific advances in the diagnosis and treatment of multiple myeloma have been made in recent years. Join Sagar Lonial, MD, and panelists Jonathan Kaufman, MD, and Ajay Nooka, MD, MPH, as they discuss the changes made by the International Myeloma Working Group to the definition of myeloma, the current ... more >>
    J. Kaufman, MD
    S. Lonial, MD
    A. Nooka, MD, MPH
  • Hematology Mastery in Multiple Myeloma
  • Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... more >>
    N. Raje, MD
  • Clinical Context: Multiple Myeloma

  • Clinical Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma.

    The curriculum includes four case studies at the point of care and MedPage Today ...
    more >>
    K. Anderson, MD
  • Clinical Context: Multiple Myeloma

  • Curriculum In Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma. The curriculum includes six case studies at the point of care, a webcast, ...
    more >>
    N. Raje, MD
  • Curriculum In Context: Multiple Myeloma

  • Curriculum In Context: Multiple Myeloma is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple myeloma. The curriculum includes six case studies at the point of care and MedPage ...
    more >>
    K. Anderson, MD
  • Case-Based Video Vignettes: Leukemia
  • This free point-of-care clinical companion focuses on the treatment and management of leukemia - €”including guidance on second-generation tyrosine kinase inhibitors (TKIs) that were recently approved for first-line therapy - through a collection of patient video case vignettes.
    J. Radich, MD
    M. Talpaz, MD
  • Lymphoma Video Vignettes
  • Stephanie A. Gregory, MD chairs this free point-of-care clinical companion that focuses on the treatment and management of lymphomas - €”including B-cell lymphoma, aggressive B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma and more - through a collection of six patient video case vignettes.
    S. Gregory, MD
  • Chronic Lymphocytic Leukemia @Point of Care
  • Recently approved targeted therapies and emerging immunotherapies for chronic lymphocytic leukemia (CLL) are transforming patient outcomes and the standard of care. To achieve the best patient outcomes, clinicians need to implement individualized treatment plans based upon evaluation of patient ... more >>
    S. Gregory, MD
  • Multiple Myeloma @Point of Care
  • This point-of-care eHandbook delivers a thorough yet concise review of multiple myeloma (MM), its diagnosis and prognosis, and the latest evidence-based data on treatment strategies with insights from top clinical specialists on the novel and emerging therapies that are revolutionizing the management of MM. ... more >>
    S. Lonial, MD
  • Multiple Myeloma @Point of Care
  • This point-of-care eHandbook delivers a thorough yet concise review of multiple myeloma (MM), its diagnosis and prognosis, and the latest evidence-based data on treatment strategies with insights from top clinical specialists on the novel and emerging therapies that are revolutionizing the management of MM. ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Focus on the Role of Proteasome Inhibitors in the Management of Multiple Myeloma – Webcast
  • Clinicians need to know how to incorporate proteasome inhibitors into treatment plans for patients with multiple myeloma, whether they are newly diagnosed or are experiencing relapsed/refractory disease. Join our co-faculty Sagar Lonial, MD, and Kenneth C. Anderson, MD, for this webcast, Focus on the Role of ... more >>
    S. Lonial, MD
  • Leukemia — Practice Tools to Manage Patients with Chronic Phase CML – Practice Tool
  • Download this free tips card on chronic phase CML management, which contains definitions and milestones of response to first-line therapy, and outlines next steps for patients with incomplete/no response to initial therapy, with and without resistance mutations.
  • Multiple Myeloma — High-Risk Relapsing MM: Retreatment With Immunomodulatory Therapy – Case Study
  • Determination of the best treatment for a high-risk multiple myeloma patient is based on a complex set of factors, including risk evaluation, patient comorbidities, patient desires, and the need to achieve a satisfactory response as quickly as possible. In this case, Dr. Lentzsch discusses the problems ... more >>
    S. Lentzsch, MD, PhD
  • Multiple Myeloma — Relapsing/Refractory Multiple Myeloma in a High Risk Patient: Efficacy With Monoclonal Antibody Therapy as Part of Triple Therapy – Case Study
  • Choosing the appropriate therapy for transplant-deferred patients with relapsed multiple myeloma (MM) can be challenging; there are now emerging combination treatments available, each with their own efficacy and safety profiles. This case illustrates the real-life case scenario of a patient with relapsed MM ... more >>
    N. Raje, MD
  • Multiple Myeloma — Treatment of a Relapsing High-Risk Multiple Myeloma Patient – Case Study
  • Today there are many options for the treatment of patients with relapsed multiple myeloma, as well as more treatments in development. This case illustrates the real-life scenario of a patient with relapsed multiple myeloma with evolution of his disease at the time of relapse introducing a high-risk ... more >>
    S. Kumar, MD
  • Multiple Myeloma — Treatment of a Patient with Relapsed/Refractory Multiple Myeloma and No Comorbidities – Case Study
  • Today there are multiple options for the treatment of patients with relapsed or refractory multiple myeloma, as well as further treatments in development. This case illustrates the real-life scenario of a patient with relapsed, bortezomib-refractory multiple myeloma, and discusses the treatment options ... more >>
    S. Bringhen, MD, PhD
  • Multiple Myeloma — Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma – Case Study
  • High-risk multiple myeloma is challenging to manage, as these patients tend to have aggressive disease, transient responses to treatment, and short overall survival. This case illustrates the real-life scenario of a patient with high-risk multiple myeloma and disease progression after initial treatment with ... more >>
    J. Shah, MD
  • Multiple Myeloma — Case Study: Role of Immunomodulatory Drug Therapy in a Patient with Refractory Multiple Myeloma – Case Study
  • Today there have been many scientific advances resulting in newly approved treatment options, as well as many more in development, that offer patients with relapsing or refractory multiple myeloma (MM) opportunities to prolong progression-free and overall survival. This case illustrates the real-life scenario ... more >>
    K. Anderson, MD
  • Multiple Myeloma — High-Risk Relapsing MM Patient: Efficacy of a Proteasome Inhibitor – Case Study
  • Patients who are at high risk for progression and are in good clinical condition should be considered for induction therapy with a novel agent and autologous stem cell transplantation . In this case, Dr. Bringhen discusses induction therapy and presents evidence to support the use of proteasome inhibitor ... more >>
    S. Bringhen, MD, PhD
  • Multiple Myeloma — Multiple Myeloma Case Study: Refractory MM Patient: Efficacy with Immunomodulatory Therapy – Case Study
  • Patients with multiple myeloma (MM) who are refractory after two prior regimens have a poor prognosis. However, newer treatments provide effective options for these challenging patients. In this case study, Sara Bringhen, MD, PhD, discusses the importance of choice of treatment for an elderly patient with ... more >>
    S. Bringhen, MD, PhD
  • Multiple Myeloma — Relapsed/Refractory MM in a Higher-Risk Patient: Efficacy with Proteasome Inhibitor Therapy – Case Study
  • For patients with multiple myeloma who have relapsed or are refractory, adverse effects from prior therapies further complicate the choice of continued treatment. In this case presentation, Dr. Vij discusses options offered by a new proteasome inhibitor for the therapy of relapsed patients who have ... more >>
    R. Vij, MD
  • Multiple Myeloma — Relapsing MM in a High-Risk Patient: Efficacy with Proteasome Inhibitor Retreatment – Case Study
  • Bortezomib and lenalidomide, either together or with other drugs, have become mainstays of multiple myeloma therapy. However, until recently, patients who relapse on these treatments have had limited alternatives. In this case presentation, Dr. Ravi Vij discusses options offered by a new proteasome inhibitor ... more >>
    R. Vij, MD